The Medicare Advantage 2027 Proposed Rule: A Mixed Bag for Health Tech Investors

Disclaimer: The views and opinions expressed in this essay are solely my own and do not reflect the views of my employer, Datavant, or any other organization with which I am affiliated.

---

If you are interested in joining my generalist healthcare angel syndicate, reach out to trey@onhealthcare.tech or send me a DM. Accredited investors only.

---

Abstract

The CMS Contract Year 2027 Medicare Advantage and Part D proposed rule represents a significant regulatory moment for healthcare entrepreneurs and investors. This analysis examines the key provisions affecting health tech innovation, including expanded telehealth coverage, enhanced health equity requirements, new prior authorization restrictions, and technology-enabled care delivery models. For angel investors, the rule creates distinct opportunities in remote patient monitoring, social determinants of health infrastructure, and AI-driven utilization management while simultaneously raising concerns about plan margin compression and regulatory compliance overhead. Understanding these dynamics is essential for making informed investment decisions in the Medicare Advantage ecosystem, which now serves over 33 million beneficiaries and represents roughly half of all Medicare enrollment.

Table of Contents

Introduction: Why This Rule Matters for Your Portfolio

The Big Picture: MA Market Dynamics and Plan Economics

Telehealth Permanence and the RPM Gold Rush

Health Equity Requirements: Building Infrastructure for SDOH

Prior Authorization Reforms: Pain Points and Opportunities

Technology-Enabled Care Models: VBC Gets Real

Supplemental Benefits Expansion: The Innovation Sandbox

Plan Margin Pressure: The Hidden Tax on Everyone

What This Means for Different Investment Stages

Sectors to Watch and Sectors to Worry About

Conclusion: Positioning for 2027 and Beyond

Introduction: Why This Rule Matters for Your Portfolio

Every year CMS drops a massive proposed rule for Medicare Advantage that makes everyone in healthcare either panic or celebrate depending on which part of the ecosystem they occupy. The Contract Year 2027 rule is no different. What makes this one particularly interesting for those of us writing checks into health tech companies is that it’s happening at an inflection point where MA plans are simultaneously dealing with margin compression, higher medical costs, and pressure to demonstrate actual value from all the technology they’ve been buying. The rule also comes alongside a separate regulatory relief RFI that CMS put out asking for feedback on what regulations are wasteful or burdensome, which tells you something about the administration’s mindset going into 2027.

For angel investors, this isn’t just regulatory wonkery. The MA market is enormous and growing. We’re talking about 33 million lives, roughly 54% of Medicare enrollment, and plans that collectively spend over $450 billion annually. When CMS changes the rules of the game, it directly impacts which companies can succeed, which business models make sense, and where capital should flow. I’ve watched too many promising health tech startups build products perfectly suited for a regulatory environment that no longer exists, or miss massive opportunities because they didn’t see the policy winds shifting.

This essay breaks down what’s actually in this rule, what it means for different types of health tech companies, and where I see the opportunities and risks for early-stage investors. I’m going to focus on the provisions that actually matter for startups and venture-backed companies rather than getting lost in the actuarial weeds. And I’ll be honest about where I think this creates headwinds versus tailwinds, because the last thing we need is more bullish pattern matching that ignores real constraints.

The Big Picture: MA Market Dynamics and Plan Economics